Drug Type Biological products |
Synonyms NN/sTNF-R2, sTNF R2 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization NaNotics LLCStartup |
Active Organization NaNotics LLCStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
AS | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Brain Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Breast Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Colorectal Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Esophageal Carcinoma | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Head and Neck Neoplasms | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Hodgkin's Lymphoma | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Liver Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Lung Cancer | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |
Male Genital Neoplasms | Preclinical | US | NaNotics LLCStartup | 05 Dec 2023 |